The major role of peripheral release of histamine and 5-hydroxytryptamine in formalin-induced nociception.
Formalin injected subcutaneously into the paw is a widely used model of pain. This procedure evokes a short-lasting period of flinching (phase 1) and a long-lasting period of intense flinching (phase 2) following a very short period of quiescence. Phase 2 has been extensively used to support the involvement of central (spinal cord) sensitization in inflammatory hyperalgesia. The present study evaluated the contribution of stimulation of peripheral nociceptors by the release of endogenous mediators at the site of lesion. The participation of histamine and 5-hydroxytryptamine was demonstrated by the treatment of the rat hindpaws with selective histamine H1 (pyrilamine and meclizine) and histamine H2 (cimetidine) receptor antagonists or selective 5-hydroxytryptamine(1A) (WAY100,135) and 5-hydroxytryptamine(4/3) (tropisetron) receptor antagonists. The co-administration of pyrilamine or meclizine with formalin (1%) significantly reduced phases 1 and 2, while cimetidine had no effect. Pyrilamine administration during the period of quiescence (10min after formalin administration) caused strong dose-related inhibition of phase 2. The co-administration of tropisetron with formalin caused a blockade of both phases, while with WAY100,135 caused only inhibition of the phase 2. In contrast, tropisetron administrated during the period of quiescence did not cause antinociception. Histamine and 5-hydroxytryptamine receptors could be strongly activated in naïve animals by administration of a mixture of both agonists or compound 48/80 (2microg/paw) which is known to release both mediators from mast cells. Pretreatment of the paws with a mast cell stabilizer, sodium cromoglycate, significantly reduced the second phase of the formalin injection model. From these results we suggest that phases 1 and 2 of the formalin test are dependent upon the ongoing afferent input. Furthermore, while histamine H1 participates in both phases, 5-hydroxytryptamine(4/3) participates in phase 1 and 5-hydroxytryptamine(1A) in phase 2.
Parada
C A
CA
Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, USP, CEP 14049-900, Ribeirão Preto-SP, Brazil.
Tambeli
C H
CH
Cunha
F Q
FQ
Ferreira
S H
SH
D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D002927:Cimetidine / Q000494:pharmacology; D004205:Cromolyn Sodium / Q000494:pharmacology; D006632:Histamine / Q000378:metabolism*; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D008468:Meclizine / Q000494:pharmacology; D009475:Neurons, Afferent / Q000378:metabolism*; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism*; D010146:Pain / Q000378:metabolism*; D010147:Pain Measurement; D010879:Piperazines / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology; D000077526:Tropisetron; D003189:p-Methoxy-N-methylphenethylamine / Q000494:pharmacology
D018927:Anti-Asthmatic Agents; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D007211:Indoles; D010879:Piperazines; D012702:Serotonin Antagonists; C081293:WAY 100135; D012701:Serotonin; D008468:Meclizine; D003189:p-Methoxy-N-methylphenethylamine; D000077526:Tropisetron; D002927:Cimetidine; D006632:Histamine; D011738:Pyrilamine; D004205:Cromolyn Sodium